FDA approves Sanofi’s quadrivalent flu vaccine for over-65s
pharmafile | November 6, 2019 | News story | Research and Development, Sales and Marketing | FDA, Fluzone, Sanofi, flu, influenza, pharma
Sanofi’s quadrivalent influenza vaccine Fluzone High Dose has secured FDA approval in adult patients over the age of 65 for the prevention of two A and two B strains of the virus.
The approval was based on Phase 3 data in which the quadrivalent Fluzone formulation proved itself non-inferior to two trivalent formulations of the therapy in terms of immunogenicity, meeting the trial’s primary endpoint.
The approval follows the decision from the FDA in 2009 to authorise the High Dose formulation as a trivalent vaccine, covering two strains of influenza A and one of influenza B. It means that Sanofi has now fully transitioned to quadrivalent flu products in the US market.
“Increasing protection and delivering improved influenza vaccines are critical to public health,” said David Loew, Sanofi Executive Vice President and head of Sanofi Pasteur. “We are excited to build upon the success of trivalent Fluzone High-Dose with this FDA approval to expand protection for an additional B strain. We have submitted filings with additional regulatory bodies outside the US and anticipate approval in the European Union next spring.”
Matt Fellows
Related Content
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, …